ADMA Biologics Inc $ADMA Shares Sold by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC has significantly reduced its stake in ADMA Biologics by 69.6%, owning 30,208 shares worth $599,000 after selling over 69,000 shares in the first quarter.
• ADMA Biologics reported a net margin of 44.06% and a revenue increase of 13.8% year-over-year, posting $0.15 EPS, exceeding analysts' expectations.
• Insider trading activity included significant share sales by directors, with Jerrold B. Grossman and Lawrence P. Guiheen selling 10,000 and 20,000 shares respectively in June.

HighTower Advisors LLC trimmed its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 69.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 30,208 shares of the biotechnology company's stock after selling 69,173 shares during the quarter. HighTower Advisors LLC's holdings in ADMA Biologics were worth $599,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of ADMA. Public Sector Pension Investment Board increased its holdings in ADMA Biologics by 27.3% in the 1st quarter. Public Sector Pension Investment Board now owns 749,702 shares of the biotechnology company's stock worth $14,874,000 after buying an additional 160,762 shares during the period. Independent Advisor Alliance acquired a new stake in ADMA Biologics during the 1st quarter valued at approximately $1,775,000. Nuveen LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at $93,543,000. Entropy Technologies LP acquired a new stake in shares of ADMA Biologics in the first quarter worth $338,000. Finally, Invesco Ltd. increased its stake in shares of ADMA Biologics by 13.9% in the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company's stock worth $255,279,000 after acquiring an additional 1,570,649 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

ADMA stock traded down $0.22 during midday trading on Thursday, hitting $16.68. 646,288 shares of the stock traded hands, compared to its average volume of 3,113,984. ADMA Biologics Inc has a 1-year low of $13.50 and a 1-year high of $25.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The stock's fifty day simple moving average is $17.73 and its 200-day simple moving average is $18.92. The firm has a market cap of $3.98 billion, a P/E ratio of 19.41 and a beta of 0.54.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. During the same period in the prior year, the company posted $0.13 EPS. The company's revenue for the quarter was up 13.8% on a year-over-year basis. On average, analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of research reports. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial lifted their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $27.67.

Insiders Place Their Bets

In other ADMA Biologics news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director directly owned 478,194 shares of the company's stock, valued at approximately $10,190,314.14. This trade represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the company's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 455,621 shares of company stock worth $9,461,633. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.